Legend Biotech Corp - LEGN Net earnings per share for the last 12 months

Legend Biotech Corp. (LEGN) - corporate logo

The effective alliance with J&J regarding CARVYKTI confirms the managerial success of Legend Biotech (LEGN). The 12-month YoY change in net income per share reflects this trend, where the parameter value equals 99.00. Stability is maintained by a staff of top biologists attracted by stock options, while the high cost of therapy, covered by insurance, guarantees the company exceptional pricing power.

legendbiotech.com (LEGN): Earnings per share for the last twelve months from 02/11/2024 to 11/12/2026

Financial and market metric breakdowns for Legend Biotech Inc. (LEGN)

- current price and projected stock value:
Price Performance Chart legendbiotech.com|LEGN - Analyst Consensus Forecast
- issuer market value details:
Market Valuation Legend Biotech Corp|LEGN - Enterprise Value
- book capitalization data:
Net Asset Value per Share Legend Biotech|LEGN - Company Book Value|Market Value to Book Value Ratio legendbiotech.com|LEGN - Aggregate Company Assets
- company total debt and liquidity indicators:
Debt to Equity Legend Biotech|LEGN - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Legend Biotech Corp.|LEGN - Company Aggregate Debts|Debt to Net Assets Legend Biotech Corp|LEGN - Company Long-Term Debts|Short-Term Debt Legend Biotech|Immediate Liquidity Ratio legendbiotech.com
- net income and valuation ratios data:
LEGN - Net Profit|Expected Net Profit Legend Biotech|LEGN - Price to Earnings Ratio|Future Price to Earnings Multiple Legend Biotech Corp|LEGN - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Legend Biotech Corp|LEGN - Operating profit EBITDA|Earnings per share for the trailing year Legend Biotech|LEGN - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months legendbiotech.com|LEGN - Earnings per share growth in current year|Expected earnings per share trend next year Legend Biotech
Fundamental company valuation:LEGN legendbiotech.com
Flagship merchandise of Legend Biotech Corp.

An investment audit of Legend Biotech (LEGN) requires an analysis of profit dynamics, where the annual growth of basic net income per share (TTM) measures the percentage change in EPS over a rolling year relative to the previous period. This metric reflects the scaling efficiency of automated gene therapy production, allowing this chart to assess the extent to which the technological sterility of bioreactors converts into real growth in shareholder value.

Competitor analysis for Legend Biotech

Earnings per share for the trailing year SANA (sana.com)|AUTL: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Allogene Therapeutics, Inc.|RNAC (Cartesian Therapeutics Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Cellectis Biotherapeutics CLLS|Earnings per share for the last twelve months Caribou Biosciences (CRBU)|Earnings per share for the last twelve months TIL (instilbio.com)|Earnings per share for the last twelve months Genenta Science GNTA|Century Tx - Earnings per share for the last twelve months|JSPR: Net earnings per share for the last 12 months|Earnings per share for the trailing year SNTI (Senti Biosciences, Inc.)|ADAP: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year CERo Therapeutics Holdings CERO|TCRT (Alaunos Therapeutics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Achilles Tx ACHL|Earnings per share for the last twelve months Cargo Therapeutics (CRGX)|Poseida Corp - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) TSVT (2seventy bio, Inc.)|gracellbio.com (GRCL) - Net earnings per one share for the last twelve months